NCT02688647View on ClinicalTrials.gov

A 2-Part, Phase 2 Open-label and Crossover Study of Belumosudil for Treatment of Idiopathic Pulmonary Fibrosis

PHASE2CompletedINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

May 26, 2016

Primary Completion Date

April 13, 2021

Study Completion Date

April 13, 2021

Conditions
Idiopathic Pulmonary Fibrosis
Interventions
DRUG

Belumosudil

OTHER

BSC

Treatment/drug as determined by each subject's prescribing physician

Trial Locations (10)

15213

University of Pittsburgh Medical Center, Pittsburgh

27403

Pulmonix, LLC, Greensboro

29425

Medical University of South Carolina, Charleston

30106

Piedmont Healthcare Pulmonary and Critical Care Research, Austell

32803

Central Florida Pulmonary Group, PA, Orlando

33765

St. Francis Medical Institute, Clearwater

34741

Pulmonary Disease Specialists, PA, d/b/a PDS Research, Kissimmee

85006

Pulmonary Associates, PA, Phoenix

85724

University of Arizona, Tucson

95817

UC Davis Medical Center, Division of Pulmonary/CC/SM, Sacramento

All Listed Sponsors
lead

Kadmon Corporation, LLC

INDUSTRY

NCT02688647 - A 2-Part, Phase 2 Open-label and Crossover Study of Belumosudil for Treatment of Idiopathic Pulmonary Fibrosis | Biotech Hunter | Biotech Hunter